What You Should Know:
– Absci, a generative AI drug creation company, and PrecisionLife, a pioneer in computational biology for complex chronic diseases, have announced a powerful partnership to develop a joint portfolio of potential therapeutics.
– This collaboration aims to leverage the strengths of both companies to address unmet medical needs and accelerate drug development.
Combining Expertise for Faster, Precision-Driven Drug Discovery
Key aspects of the partnership include:
– Joint pipeline: Absci and PrecisionLife will work together to discover and develop biotherapeutics for up to five mutually agreed-upon targets and indications.
– Shared success: Both companies will actively participate in target selection, program development, and potential future commercialization.
– Unveiling complex diseases: PrecisionLife’s expertise will help Absci’s AI pinpoint the most promising targets for effective therapeutic development.
With this partnership, Absci has secured ten new Active Programs in 2023, surpassing its target for the year. This signifies the growing traction and value proposition of their AI-powered drug creation platform.
“This collaboration combines our complementary strengths to create a high-value pipeline of novel therapeutics. PrecisionLife’s disease biology insights complement our AI, accelerating the development of potentially effective treatments for patients in need,” said Sean McClain, Absci Founder & CEO.
